Law
Seminars International (LSI) will be offering a one-hour telebriefing on "The Myriad
Decision: Practical Implications for
Biotechnology Companies Protecting IP Assets" on July 17,
2013 from 3:00 to 4:00 pm (Eastern). Dr.
Barbara R. Rudolph of Finnegan
Henderson Farabow Garrett & Dunner LLP will moderate a panel that
includes Jennifer L. Swize of Jones Day
and Courtenay C. Brinckerhoff of Foley
& Lardner LLP. The panel will
discuss the Myriad decision and the possible implications for patent
procurement, patent litigation, the biotechnology industry, and the future of
medical research. Among the topics to be
covered are:
•
Impact of the Myriad Decision on
patents for genetic research
•
How the decision distinguishes between natural and synthetic gene sequences
•
Legal and business implications for the biotech industry
•
New strategies for protecting DNA-based intellectual property moving forward
A
Q&A will follow the presentation and last for up to 30 minutes.
The
registration fee is $150 per caller and $100 for each additional person on the
same line who desires continuing education credit. Those interested in registering for the
telebriefing, can do so here.
Comments